[1] GOH K L,CHAN W K,SHIOTA S,et al. Epidemiology of Helicobacter pylori infection and public health implications[J].Helicobacter,2011,16 Suppl 1(1):1-9.
[2] 中华医学会,中华医学会杂志社,中华医学会全科医学分会,等.幽门螺杆菌感染基层诊疗指南(2019年)[J].中华全科医师杂志,2020,19(5):397-402.
[3] WANG F,MENG W,WANG B,et al. Helicobacter pylori-induced gastric inflammation and gastric cancer[J].Cancer Lett,2014,345(2):196-202.
[4] CORREA P.Gastric cancer:overview[J].Gastroenterol Clin North Am,2013,42(2):211-217.
[5] WATARI J,CHEN N,AMENTA P S,et al. Helicobacter pylori associated chronic gastritis,clinical syndromes,precancerous lesions,and pathogenesis of gastric cancer development[J].World J Gastroenterol,2014,20(18):5461-5473.
[6] LI H,XU C X,GONG R J,et al. How does Helicobacter pylori cause gastric cancer through connexins:an opinion review[J].World J Gastroenterol,2019,25(35):5220-5232.
[7] 张万岱,胡伏莲,萧树东,等.中国自然人群幽门螺杆菌感染的流行病学调查[J].现代消化及介入诊疗,2010,15(5):265-270.
[8] LEE Y C,CHIANG T H,CHOU C K,et al. Association between Helicobacter pylori eradication and gastric cancer incidence:a systematic review and meta-analysis[J].Gastroenterology,2016,150(5):1113-1124.e5.
[9] ARGUETA E A,MOSS S F.The prevention of gastric cancer by Helicobacter pylori eradication[J].Curr Opin Gastroenterol,2021,37(6):625-630.
[10] 张晓冬,张大涯,陈世锔,等.海口市幽门螺杆菌感染现状与相关危险因素调查[J].现代消化及介入诊疗,2024,29(4):393-397.
[11] SMYTH E C,NILSSON M,GRABSCH H I,et al. Gastric cancer[J].Lancet,2020,396(10251):635-648.
[12] 吕农华,谢川.我国幽门螺杆菌感染研究的回顾与展望[J].中华消化杂志,2021,41(4):217-220.
[13] LI M,SUN Y,YANG J,et al. Time trends and other sources of variation in Helicobacter pylori infection in mainland China:a systematic review and meta-analysis[J].Helicobacter,2020,25(5):e12729.
[14] 李诺,刘鹏亮,赵志峰.新疆塔城地区幽门螺杆菌感染及抗体分型状况分析[J].中国实验诊断学,2023,27(4):460-461.
[15] 施恩,张毅.青岛地区成年体检人群幽门螺杆菌感染与14种食物不耐受的相关性分析[J].现代医学,2022,50(7):853-860.
[16] 阮玉凤,冯伟,杨小芹,等.上海市2023年社区居民家庭内幽门螺杆菌感染现状调查[J].中国乡村医药,2024,31(11):54-56.
[17] 刘国英,姚浪,邓宁,等.31 764例健康体检人群幽门螺杆菌感染影响因素分析[J].健康体检与管理,2023,4(3):251-257.
[18] 杨德红,朱传会,张晓勇,等.南京市建邺区60~80岁老年人群幽门螺旋杆菌感染及与胃蛋白酶原相关性分析[J].公共卫生与预防医学,2022,33(3):138-141.
[19] 张博,张俊娟,马彩霞,等.学龄期儿童幽门螺旋杆菌感染影响因素的Logistic回归模型构建及ROC曲线分析[J].实用医院临床杂志,2024,21(3):129-133.
[20] 张思玮.我国城市人群幽门螺杆菌感染率低、耐药率高[N].中国科学报,2024-03-13(3).
[21] 王楠,刘雨,陈改杰.健康体检人群幽门螺杆菌感染现状分析[J].河南医学研究,2018,27(14):2548-2549.
[22] 方玲,吴远,林燕生,等.深圳市体检人群幽门螺杆菌感染相关因素分析[J].罕少疾病杂志,2010,17(6):22-24.
[23] ZHOU X Z,LYU N H,ZHU H Y,et al. Large-scale,national,family-based epidemiological study on Helicobacter pylori infection in China:the time to change practice for related disease prevention[J].Gut,2023,72(5):855-869.
[24] 汪俊虎,朱盼盼,刘芳芳,等.1 096例健康体检者幽门螺杆菌感染状况及其影响因素[J].中华健康管理学杂志,2024,18(3):214-216.
[25] 吴洁,张明英,李霞,等.5 020例健康体检人群幽门螺杆菌感染情况调查[J].中华健康管理学杂志,2021,15(5):491-494.
[26] 宋琼,洪海燕,万政策,等.幽门螺杆菌与系统性炎症指标的相关性分析[J].临床消化病杂志,2021,33(6):398-402.
[27] 刘学欣,陈文燕,孟翠巧,等.幽门螺杆菌感染与白细胞计数及其危险因素相关性分析[J].中国病原生物学杂志,2023,18(10):1147-1151,1157.
[28] YANG H,HU B.Immunological perspective:Helicobacter pylori infection and gastritis[J].Mediators Inflamm,2022:2944156.
[29] SUERBAUM S,MICHETTI P.Helicobacter pyloriInfection[J].N Engl J Med,2002,347(15):1175-1186.
[30] FU H W.Helicobacter pylori neutrophil-activating protein:from molecular pathogenesis to clinical applications[J].World J Gastroenterol,2014,20(18):5294-5301.
[31] MATSUZAKI J,TSUGAWA H,KASHIWAZAKI Y,et al. Neutrophil-activating protein polymorphism of Helicobacter pylori determines the host risk of dyspepsia[J].Cell Mol Gastroenterol Hepatol,2019,8(2):295-297.e6. |